[Kovaltry® for the replacement therapy in patients with Hemophilia A]
DOI:
https://doi.org/10.7175/fe.v17i2.1250Keywords:
Hemophilia A, Recombinant factor VIII, Replacement therapyAbstract
[Article in Italian]References
Istituto Superiore di Sanità. Registro Nazionale Coagulopatie Congenite. Rapporto 2013.F. Abbonizio, A. Giampaolo, R. Arcieri, H. J. Hassan e Associazione Italiana Centri Emofilia (AICE) 2015, iii, 72 p. Rapporti ISTISAN 15/14
Committee for medicinal products for human use (CHMP). Guideline on the clinical investigation of recombinant and 4 human plasma-derived factor VIII products. EMA/CHMP/BPWP/144533/2009 rev. 1. 21 maggio 2015
Rocino A, Coppola A, Franchini M, et al. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfusion 2014; 12: 575-98; http://dx.doi.org/10.2450/2014.0223-14
Strawczynski H, Stachewitsch A, Morgenstern G, et al. Delivery of care to hemophilic children: home care versus hospitalization. Pediatrics 1975; 51: 986-91
Kavakli K, Yang R, Rusen L, et al. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost 2015; 13: 360-9; http://dx.doi.org/10.1111/jth.12828
Saxena K, Lalezari S, Oldenburg J, et al. Pharmacokinetics, efficacy, and safety of BAY 81-8973, a full-length plasma-protein-free recombinant factor VIII product: results from the LEOPOLD trial. J Thromb Haemost 2013; 11: 928
Ljung R, Kenet G, Mancuso ME, Kaleva V, Rusen L, Tseneklidou-Stoeter D. , Michaels L.A., Shah A, Hong W, BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe hemophilia A: results of the LEOPOLD Kids Trial. Haemophilia 2016; 22: 354-60; http://dx.doi.org/10.1111/hae.12866
Advate® – Riassunto delle Caratteristiche di Prodotto
Helixate Nexgen® – Riassunto delle Caratteristiche di Prodotto
Kogenate Bayer® – Riassunto delle Caratteristiche di Prodotto
Recombinate® – Riassunto delle Caratteristiche di Prodotto
Refacto AF® – Riassunto delle Caratteristiche di Prodotto
NovoEight® – Riassunto delle Caratteristiche di Prodotto
Nuwiq® – Riassunto delle Caratteristiche di Prodotto
Kovaltry® – Riassunto delle Caratteristiche di Prodotto
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
